204.jpg)
Novavax is doubling its COVID-19 vaccine manufacturing capacity to 200 crore doses under an agreement with Serum Institute of India, the US company said on Tuesday. As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, which is dubbed NVX‑CoV2373. The US company’s vaccine is currently in mid-stage trials.
Novavax is doubling its COVID-19 vaccine manufacturing capacity to 200 crore doses under an agreement with Serum Institute of India, the US company said on Tuesday. As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, which is dubbed NVX‑CoV2373. The US company’s vaccine is currently in mid-stage trials.
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
5.jpeg)
4.jpeg)
6.jpeg)
5.jpeg)
